High cost, low volume care in haemophilia.
作者信息
Selway J
出版信息
BMJ. 1998 May 2;316(7141):1391. doi: 10.1136/bmj.316.7141.1391a.
Abstract
摘要
相似文献
1
High cost, low volume care in haemophilia.血友病中的高成本、低容量治疗
BMJ. 1998 May 2;316(7141):1391. doi: 10.1136/bmj.316.7141.1391a.
2
Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.仅接受重组因子（F）VIII治疗或至少接受过一次血浆源性FVIII或FIX浓缩剂治疗的血友病儿童中抗人细小病毒B19 IgG抗体的患病率：来自法国血友病队列的结果
Br J Haematol. 2002 Feb;116(2):383-9.
3
Human parvovirus B19 infection in persons with haemophilia.血友病患者中的人细小病毒B19感染
Thromb Haemost. 1998 Aug;80(2):351.
4
Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.年轻男性甲型血友病患者中的人细小病毒B19：与治疗产品暴露及关节活动范围受限的关联
Transfusion. 2004 Aug;44(8):1179-85. doi: 10.1111/j.1537-2995.2004.04029.x.
5
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.血友病患者首次输注两种高纯度、病毒减毒的凝血因子VIII浓缩剂后感染人细小病毒B19。
Am J Hematol. 1992 Mar;39(3):228-30. doi: 10.1002/ajh.2830390315.
6
Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.一名既往未经治疗的血友病患者输注了血浆源性、单克隆抗体纯化的凝血因子VIII浓缩物后，因原发性人细小病毒B19感染导致短暂性再生障碍性贫血。
J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):74-6.
7
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates.在接受血浆源性凝血因子浓缩物治疗的出血性疾病患者中，细小病毒B19持续传播的证据。
Transfusion. 2013 May;53(5):1143-4. doi: 10.1111/trf.12153.
8
Human parvovirus B19 after concentrates for haemophilia.血友病浓缩制剂中的人细小病毒B19
Lancet. 1994 Jun 18;343(8912):1566. doi: 10.1016/s0140-6736(94)92963-7.
9
Parvovirus B19 antibodies in patients with haemophilia A.甲型血友病患者中的细小病毒B19抗体。
Thromb Haemost. 1995 Mar;73(3):555-6.
10
Absence of evidence of parvovirus B19 transmission by plasma-derived clotting concentrates derived from B19V nucleic acid technology-tested plasma and including effective steps for the inactivation or removal of nonenveloped viruses.通过源自经B19V核酸技术检测的血浆且包含有效灭活或去除无包膜病毒步骤的血浆源性凝血浓缩物传播细小病毒B19的证据缺失。
Transfusion. 2013 May;53(5):1141-2. doi: 10.1111/trf.12140.
本文引用的文献
1
Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses.仅接受被认为对人类免疫缺陷病毒和丙型肝炎病毒安全的凝血因子浓缩物治疗的血友病患者中细小病毒B19、巨细胞病毒、甲型肝炎病毒和戊型肝炎病毒抗体的血清流行率。
Haemophilia. 1995 Apr;1(2):115-7. doi: 10.1111/j.1365-2516.1995.tb00050.x.
2
High cost, low volume care: the case of haemophilia.
BMJ. 1997 Oct 18;315(7114):962-3. doi: 10.1136/bmj.315.7114.962.
3
Eliminating parvovirus B19 from blood products.
Lancet. 1994 Mar 26;343(8900):798. doi: 10.1016/s0140-6736(94)91878-3.
4
Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.通过用有机溶剂和去污剂处理以灭活病毒的凝血因子VIII浓缩物将甲型肝炎传播给血友病患者。意大利协作组。
Ann Intern Med. 1994 Jan 1;120(1):1-7. doi: 10.7326/0003-4819-120-1-199401010-00001.
Zotero 插件